Preview

Rational Pharmacotherapy in Cardiology

Advanced search

DIHYDROPYRIDINE CALCIUM ANTAGONISTS: DATA OF EVIDENCE BASED MEDICINE AND RECOM-MENDATIONS ON PRACTICAL USE

https://doi.org/10.20996/1819-6446-2007-3-1-55-59

Full Text:

Abstract

The classification of calcium antagonists is presented. There were considered the results of large randomized trials, which were devoted to study of influence of dihydropyridine calcium antagonists on the risk of cardiovascular complications. The place of dihydropyridine calcium antagonists in modern recommendations on treatment of arterial hypertension and ischemic heart disease is defined. The clinical importance of differences between various presentations of dihy-dropyridine calcium antagonists is stressed.

About the Author

S. Y. Martsevich
State research center of preventative medicine, Roszdrav, Moscow
Russian Federation


References

1. Fleckenstein A., Tritthart H., Fleckenstein B., Herbst A., Grun G. Eine neue Gruppe kom-petitiver Ca++ -Antagonisten (Iproveratril, D6000, Prenylamin) mit starken Hemeffekten auf die elektromekanische Koppelung im Warmbluter-myocard. Pflugers Arch 1969: 307: R25.

2. Report of theHolland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group. Early treatment of unstable angina in the coronary care unit: a randomised double-blind placebo-controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br. Heart J. 1986; 56: 400 – 413.

3. Secondary Prevention Reinfarction Israeli Nifedipine Trial (SPRINT). A randomized in-tervention trial of nifedipine in patients with acute myocardial infarction. Eur. Heart J. 1988; 9: 354-364.

4. Brown M. J., Palmer C.R., Castaigne A. et al. Morbidity and mortality in patients random-ized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000; 356: 366-372.

5. Dahlof B., Sever P., Poulter N. et al. Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipin adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.

6. Nissen S.E., Tuzcu E.M., Libby P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2226.

7. Poole-Wilson P., Lubsen J., Kirwan B. et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): a randomised controlled trial. Lancet 2004;364:849-857.

8. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens 2003; 21: 1011-1053.

9. Management of hypertension in adults in primary care. NICE clinical guideline 34. London 2006.

10. ACC/AHA/ACP-ACIM Guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/AmericanHeart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2003; 41: 159-168.

11. Оганисян Н.С., Дмитриева Н.А., Кочетков А.М., Марцевич С.Ю. Особенности диагностики и вторичной профилактики артериальной гипертонии по результатам опроса врачей. Рациональная фармакотерапия в кардиологии 2006; 2:37-42.

12. Кукес В.Г., Сычев Д.А. Все ли пролонгированные лекарственные формы нифедипина одинаковы? Рациональная фармакотерапия в кардиологии 2006; 1:49-54.

13. Chung M., Reitberg D., Gaffney M., Singleton W. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. Am.J.Med 1987;83 (suppl.6B):10-14.

14. Kleinbloesem C.H., van Brummelen P., Faber H., Breimer D.D. Pharmacokinetics and hemodynamic effects, of long-term nifedipine treatment in hypertensive patients. J. Cardiovasc. Pharmacol. 1987; 9: 202-208.

15. Марцевич С.Ю., Алимова Е.В., Горбунов В.М. и др. Новая лекарственная форма нифедипина пролонгированного действия – Нифекард-XL: многоцентровое рандомизированное перекрестное исследование у больных артериальной гипертонией. Российский кардиологический журнал 2003; 5: 55-58


For citation:


Martsevich S.Y. DIHYDROPYRIDINE CALCIUM ANTAGONISTS: DATA OF EVIDENCE BASED MEDICINE AND RECOM-MENDATIONS ON PRACTICAL USE. Rational Pharmacotherapy in Cardiology. 2007;3(1):55-59. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-1-55-59

Views: 336


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)